CALL US:022-2204 0015 / 16 / 17
Neethikrishna, Mumbai May 04 , 2021
The scientists of Ayurevda research institutions in the country have found that Ayush 64, a poly herbal formulation developed by the Central Council for Research in Ayurvedic Sciences (CCRAS), under the Union Ministry of Ayush is useful in the treatment of asymptomatic, mild and moderate Covid-19 infection as an adjunct to standard care. Initially the drug was developed for malaria in the year 1980 and now is repurposed for Covid-19.

The Union Ministry of Ayush-Council of Scientific and Industrial Research (CSIR) collaboration has recently completed a robust multi-centre clinical trial to evaluate the safety and efficacy of Ayush 64 in the management of mild to moderate Covid-19 patients.

Ayush 64 comprises of Alstonia scholaris (aqueous bark extract), Picrorhiza kurroa (aqueous rhizome extract), Swertia chirata (aqueous extract of whole plant) and Caesalpinia crista (fine-powdered seed pulp). It is extensively studied, scientifically developed, safe and effective ayurveda formulation. This medicine is also recommended in National clinical management protocol based on Ayurveda and Yoga which is vetted by National taskforce on Covid-19 management of Indian Council of Medical Research (ICMR).

Dr N Srikanth, director general, CCRAS elaborated that additional studies on Ayush 64 are underway at reputed research institutes including CSIR-Indian Institute of Integrative Medicine (IIIM), Department of Biotechnology- Translational Health Science and Technology Institute (DBT-THSTI), ICMR-National Institute of Nutrition (NIN), All India Institute of Medical Science (AIIMS) Jodhpur and Medical Colleges including Post Graduate Institute of Medical Education & Research, Chandigarh; King George's Medical University, Lucknow; Government Medical College, Nagpur; Datta Meghe Institute of Medical Sciences, Nagpur.

He further stated that results received so far have shown the usefulness of Ayush 64 in dealing with mild and moderate Covid-19. He also added that the outcome of the seven clinical studies has revealed that Ayush 64 exhibits early clinical recovery in Covid-19 cases without further progression. In all clinical studies, Ayush 64 was found to be well tolerated and found clinically safe.

Dr Arvind Chopra, director, Centre for Rheumatic Diseases, Pune and chief clinical coordinator of Ayush–CSIR collaboration stated that Ayush 64 as an adjunct to standard of care (SoC) showed significant improvement and thus lesser period of hospitalization as compared SoC alone. He concluded that this controlled drug trial study has provided substantial evidence that Ayush 64 can be effectively and safely used to treat mild to moderate cases of Covid-19 as adjuvant to SoC.

Dr V M Katoch, chairman of the joint monitoring committee, informed that the committee has carefully reviewed the outcome of Ayush 64 study and recommended Ayush 64 in the management of asymptomatic, mild to moderate Covid-19. It is worthwhile to note that this committee has also recommended Ministry to communicate to the state licensing authorities/regulators regarding adding new indication of Ayush 64 for repurposing in the management of mild to moderate Covid-19.

Share This Story

Leave a Reply
Your name (required)   Your email (required)
Website (required)
Enter Code (Required)





That foods might provide therapeutic benefits is clearly not a new concept. ...


About Us
Contact Us
News Archives

Product Finder
Features and Articles
Chronicle Pharmabiz
Food & Bevergae News
Ingredients South Asia
Media Information
Rate Card
Copyright © 2013 Saffron Media Pvt Ltd. All Rights Reserved.
Best View in Internet Explorer(9.0) or Firefox(26.0)